Tian-Yu Cai

Tian-Yu Cai

Auto-generated profile, based on publicly available information

Tian-Yu Cai

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
TCTianyu Cai
Tianyu Cai
AGAgnès Gouble
Agnès Gouble
KBKathryn L. Black
Kathryn L. Black
ASAnna Skwarska
Anna Skwarska
ANAmmar S. Naqvi
Ammar S. Naqvi
MKMarina Konopleva
Marina Konopleva
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with poor outcomes with conventional therapy. Nearly 100% of BPDCNs overexpress interleukin 3 receptor subunit alpha (CD123). Given that CD123 is differentially expressed on the surface of BPDCN cells, it has emerged as an attractive therapeutic target. UCART123 is an investigational product consisting of allogeneic T cells expressing an anti-CD123 chimeric antigen receptor (CAR), edited with TALEN® nucleases. In this study, we examine the antitumor activity of UCART123 in preclinical models of BPDCN. We report that UCART123 have selective antitumor activity against CD123-positive primary BPDCN samples (while sparing normal hematopoietic progenitor cells) in the in vitro cytotoxicity and T cell degranulation assays; supported by the increased secretion of IFNγ by UCART123 cells when cultured in the presence of BPDCN cells. UCART123 eradicate BPDCN and result in long-term disease-free survival in a subset of primary patient-derived BPDCN xenograft mouse models. One potential challenge of CD123 targeting therapies is the loss of CD123 antigen through diverse genetic mechanisms, an event observed in one of three BPDCN PDX studied. In summary, these results provide a preclinical proof-of-principle that allogeneic UCART123 cells have potent anti-BPDCN activity.

19 September 2024 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
CDCourtney Dinardo
Courtney Dinardo
DVDivij Verma
Divij Verma
Natalia BaranNatalia Baran
Natalia Baran
TBTushar D. Bhagat
Tushar D. Bhagat
ASAnna Skwarska
Anna Skwarska
MKMarina Konopleva
Marina Konopleva

6 July 2026 in Leukemia
Verified
Journal Article
Open access
PDF file
HBHannah Beird
Hannah Beird
SKSankaranarayanan Kannan
Sankaranarayanan Kannan
JLJingjing Liu
Jingjing Liu
JCJanice Chen
Janice Chen
AOArturo Olguin
Arturo Olguin
NPNaveen Pemmaraju
Naveen Pemmaraju
Tagraxofusp is a CD123-targeted therapy comprised of a recombinant human interleukin-3 (IL-3) fused to a truncated diphtheria toxin payload. It is the first approved treatment specifically for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). To identify biomarkers of response, bone marrow samples from 12 BPDCN patients who were treated with tagraxofusp in the pivotal phase II trial (NCT02113982) were profiled longitudinally using a gene panel and single-cell RNA sequencing. Residual tumor cells following tagraxofusp expressed lower levels of TXNRD1 that would reduce the efficacy of tagraxofusp. In support of this, enzymatic inhibition of TXNRD1 resulted in higher viability of CAL-1 BPDCN cells following tagraxofusp. Responders had either wild-type or missense TET2 mutations, while transient and non-responders had at least one truncating TET2 mutation. Examples of these mutations within the catalytic domain of TET2 were constructed and transduced into cells. Missense and truncating mutants displayed reduced sensitivities to hypomethylating agents and prolonged S-phase stasis. These results suggest that the levels of TXNRD1 interact with intrinsic TET2 truncating mutations within the bone marrow to modulate patient response to tagraxofusp.

3 April 2023
Verified
Other
Open access
TCTian-Yu Cai
Tian-Yu Cai
XLXiao-Wen Liu
Xiao-Wen Liu
HZHong Zhu
Hong Zhu
JCJi Cao
Ji Cao
JZJun Zhang
Jun Zhang
BYBo Yang
Bo Yang
PDF file - 131K, Figure S4. TPZ and SN-38 decrease the rate of HIF-1alpha protein synthesis.

3 April 2023
Verified
Other
Open access
TCTian-Yu Cai
Tian-Yu Cai
XLXiao-Wen Liu
Xiao-Wen Liu
HZHong Zhu
Hong Zhu
JCJi Cao
Ji Cao
JZJun Zhang
Jun Zhang
BYBo Yang
Bo Yang
PDF file - 293K, Figure S3. TPZ enhanced the cytotoxicity elicited by topoisomerase I inhibitors under hypoxia.

3 April 2023
Verified
Other
Open access
TCTian-Yu Cai
Tian-Yu Cai
XLXiao-Wen Liu
Xiao-Wen Liu
HZHong Zhu
Hong Zhu
JCJi Cao
Ji Cao
JZJun Zhang
Jun Zhang
BYBo Yang
Bo Yang
PDF file - 59K, Figure S5. Overexpression of HIF-1alpha is associated with resistance to topoisomerase I inhibitors in HCC cells.